There are inconsistent findings regarding the effect of lipid-lowering agents on non-alcoholic fatty liver disease (NAFLD). Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is an important player in cholesterol homeostasis and intracellular lipogenesis, and PCSK9 inhibitors (PCSK9-i) have been found to be efficient for pharmacological management of hyperlipidemia.
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition / A.A. Momtazi-Borojeni, M. Banach, M. Ruscica, A. Sahebkar. - In: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. - ISSN 1751-2433. - (2022 Oct 05), pp. 1-10. [Epub ahead of print] [10.1080/17512433.2022.2132229]
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
M. RuscicaWriting – Review & Editing
;
2022
Abstract
There are inconsistent findings regarding the effect of lipid-lowering agents on non-alcoholic fatty liver disease (NAFLD). Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is an important player in cholesterol homeostasis and intracellular lipogenesis, and PCSK9 inhibitors (PCSK9-i) have been found to be efficient for pharmacological management of hyperlipidemia.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Amir Abbas Momtazi-Borojeni.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.53 MB
Formato
Adobe PDF
|
1.53 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
